Hearing News Watch

Featured image for “New Book Released: “Forensic Audiology: A Guide for the Expert Witness””
Mar. 17, 2024

New Book Released: “Forensic Audiology: A Guide for the Expert Witness”

HHTM
Plural Publishing has announced the release of a groundbreaking book tailored for audiologists seeking to expand their expertise into the realm of legal proceedings. Titled “Forensic Audiology: A Guide for the Expert Witness,” this comprehensive guide offers invaluable insights into navigating the complexities of forensic audiology within the legal system. Recognizing the gap between audiological knowledge and legal procedure, the
Featured image for “Moving the Meter for Hearing Health”
Mar. 15, 2024

Moving the Meter for Hearing Health

HHTM
by Terry Mactaggart, President and CEO, Summus Hearing  The case for extending the reach of hearing health services continues to build. Credible research summarizes country and, occasionally, continental status. Global updates are also in. Universally these studies underscore the extent of the public hearing health problem, the mounting costs it creates and, occasionally, ways in which it could be alleviated.
Featured image for “HIMSA announces Noah ES Webinar: “Lower Costs for your Hearing Care Business” on April 11th”
Mar. 15, 2024

HIMSA announces Noah ES Webinar: “Lower Costs for your Hearing Care Business” on April 11th

HHTM
Is it really less expensive to purchase on-premise software than to pay for a monthly subscription? For your average hearing care business with two offices, the price of two Noah System site licenses may be roughly the equivalent to a 4-year Noah ES subscription for three users. However, this figure doesn’t tell the whole story. Initial software price is just
Featured image for “Starkey’s Chief Audiology Officer Dr. Sara Burdak Receives Women in Business Award for Leadership Excellence”
Mar. 13, 2024

Starkey’s Chief Audiology Officer Dr. Sara Burdak Receives Women in Business Award for Leadership Excellence

HHTM
EDEN PRAIRIE, MINNESOTA – Starkey has announced that its Chief Audiology Officer and Executive Vice President of Product Strategy, Dr. Sara Burdak, has been named the Gold Winner for Woman of the Year in the manufacturing category of the Stevie Awards for Women in Business. This global award program recognizes women executives for their innovative initiatives and outstanding leadership. “Receiving this
Featured image for “Save the Date: Pathways Mini-Symposium on CAPD/Neuroaudiology”
Mar. 12, 2024

Save the Date: Pathways Mini-Symposium on CAPD/Neuroaudiology

HHTM
Pathways, in collaboration with the University of Kentucky Department of Otolaryngology – Head and Neck Surgery, is pleased to announce a virtual mini-symposium focusing on Central Auditory Processing Disorder (CAPD) and Neuroaudiology. The event will take place on Saturday, April 27, 2024 This unique event brings together renowned clinicians and researchers to delve into contemporary topics in these specialized fields.
Featured image for “Webinar Aims to Dispel Hearing Loss Myths and Stigma”
Mar. 12, 2024

Webinar Aims to Dispel Hearing Loss Myths and Stigma

HHTM
With hearing loss representing a growing yet vastly undertreated global health crisis, a new webinar looks to combat widespread misconceptions and stigma that discourage people from seeking help. The online event titled “Hearing Loss Misconceptions and Breaking Stigma” is being hosted by Tuned, a digital hearing health company providing preventive and comprehensive hearing health for employers. It will feature insights
Featured image for “Sensorion Achieves Primary Endpoint in SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation in Cochlear Implantation”
Mar. 11, 2024

Sensorion Achieves Primary Endpoint in SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation in Cochlear Implantation

HHTM
MONTPELLIER, FRANCE — Biotechnology company Sensorion has announced that it has met the primary endpoint for its Phase 2a clinical trial of SENS-401, a drug candidate aimed at preserving residual hearing after cochlear implantation. The Phase 2a trial was a multicenter, randomized, controlled, open-label study designed to evaluate the presence of SENS-401 in the inner ear fluid (perilymph) at potentially
Featured image for “New Smartphone App Uses AI to Accurately Diagnose Ear Infections in Kids”
Mar. 08, 2024

New Smartphone App Uses AI to Accurately Diagnose Ear Infections in Kids

HHTM
PITTSBURGH, PENNSYLVANIA — A team of doctors and scientists from the University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh have developed a groundbreaking smartphone app that uses artificial intelligence (AI) to accurately diagnose ear infections, known as acute otitis media (AOM), in young children. Their findings, published in the journal JAMA Pediatrics, suggest that this AI tool
Featured image for “REGAIN Hearing Loss Drug Trial Narrowly Misses Efficacy Goal, But Shows Promise for Future Development”
Mar. 07, 2024

REGAIN Hearing Loss Drug Trial Narrowly Misses Efficacy Goal, But Shows Promise for Future Development

HHTM
LONDON, UNITED KINGDOM – Results from a pioneering clinical trial suggest an experimental drug aimed at reversing hearing loss narrowly missed its primary efficacy goal, though deeper analysis provided encouraging signs that merit further development of the therapy. The REGAIN trial, a world-first study of a regenerative drug for hearing loss, found the treatment called LY3056480 did not restore hearing
Featured image for “Amplifon Reports Record Revenues and Profits in 2023, Expects Continued Growth in 2024”
Mar. 07, 2024

Amplifon Reports Record Revenues and Profits in 2023, Expects Continued Growth in 2024

HHTM
MILAN, ITALY – Global hearing care retailer, Amplifon S.p.A., announced strong financial results for 2023 today, with record revenues and profits driven by significant organic growth and acquisitions around the world. The company reported consolidated revenues of €2.26 billion for the year (~$2.47B USD), an increase of 10.2% at constant exchange rates compared to 2022. Solid organic growth of 8%